Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrous Acid SCHEMBL25420864 | 0.93 | CASP6 (0.38) | CASP6ADORA2AADORA2BMAPTALDH1A1 | |
| Nitrous Acid SCHEMBL25420865 | 0.93 | CASP6 (0.38) | CASP6ADORA2AADORA2BMAPTALDH1A1 | |
| SCHEMBL242052 | 0.90 | ALDH1A1 (0.41) | CASP6ADORA2AADORA2BALDH1A1PDE4A | |
| SCHEMBL1546524 | 0.87 | SIRT1 (0.41) | CASP6ADORA2AADORA2BALDH1A1KDM4E | |
| SCHEMBL2535640 | 0.85 | ADORA2B (0.36) | CASP6ADORA2BMAPTALDH1A1KDM4E | |
| SCHEMBL2778902 | 0.85 | CYP3A4 (0.44) | CASP6ADORA2AADORA2BMAPTKDM4E | |
| SCHEMBL1546062 | 0.84 | PDE5A (0.47) | CASP6ADORA2AADORA2BALDH1A1PDE4A | |
| SCHEMBL7356240 | 0.81 | ALDH1A1 (0.47) | CASP6ADORA2AADORA2BALDH1A1PDE4A | |
| SCHEMBL9274268 | 0.81 | CASP6 (0.37) | CASP6ADORA2AADORA2BGSK3AGSK3B | |
| SCHEMBL7743865 | 0.79 | PDE4A (0.42) | CASP6ADORA2AADORA2BMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024428-A | Novel method for synthesizing itratheophylline | 山东新华制药股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-107915735-A | The improvement in synthesis of istradefylline | 北京阜康仁生物制药科技有限公司 | 2018-04-17 | — | — | CN | claimed |
| JP-7224047-A | — | — | None | — | — | JP | disclosed |
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC | 2025-02-27 | — | — | US | disclosed |
| EP-4452279-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | Metro International Biotech, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118541157-A | Composition for treating inflammation | 麦德龙国际生物科技有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11878994-B1 | Compositions for treatment of inflammation | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| CN-117024428-A | Novel method for synthesizing itratheophylline | 山东新华制药股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023122190-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122190-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023097402-A1 | PURINE COMPOUNDS FOR TREATING DISORDERS | MARVEL BIOTECHNOLOGY (CA) | 2023-06-08 | — | — | WO | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| EP-2010505-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007110868-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110868-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
| JP-H07224047-A | PRODUCTION OF DIAMINOURACILS | NIPPON KAYAKU CO LTD | 1995-08-22 | — | — | JP | disclosed |
| US-4968672-A | DRUG DELIVERY; DIURETICS, KIDNEY DISORDERS, HYPOTENSIVE AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0092398-B1 | SUBSTITUTED 8-PHENYLXANTHINES | WARNER-LAMBERT COMPANY (US) | 1987-03-25 | — | — | EP | disclosed |
| US-4452788-A | BRONCHODILATORS | WARNER-LAMBERT COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| EP-0092398-A1 | Substituted 8-phenylxanthines | WARNER-LAMBERT COMPANY (US) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | CASP6 3507/4885ADORA2A 291/4885ADORA2B 611/4885 |
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | NQO1, NAMPT, MPO | CASP6 990/4885ADORA2A 543/4885ADORA2B 1104/4885 |
| US-11878994-B1 | Compositions for treatment of inflammation | NQO1, NAMPT, MPO | CASP6 990/4885ADORA2A 543/4885ADORA2B 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.